The gastric balloon pill is a new, non-invasive weight-loss method where a deflated balloon is swallowed in pill form and then inflated in the stomach. Known as the Allurion Balloon, this method reduces the amount of food the stomach can hold, promoting weight loss without surgery.

Another term for the Roux-en-Y gastric bypass, the Roux bypass is highly regarded for its effectiveness in helping patients lose weight and improve health conditions related to obesity. Named after the French surgeon César Roux, this procedure is a combination of both restrictive and malabsorptive techniques. It requires a lifetime commitment to dietary changes, exercise, and regular follow-up with healthcare professionals.

The "Skinny Pen" refers to a weight-loss medication called liraglutide (brand name Saxenda) that is administered through a daily injection. It works by mimicking a hormone that regulates appetite, helping patients feel fuller for longer. This treatment is often used for individuals who struggle with obesity but are not candidates for surgery or who need additional help in managing their weight post-bariatric surgery. The drug is available by prescription and is used in conjunction with diet and exercise.

Roux-en-Y Gastric Bypass (RYGB) is a popular form of bariatric surgery that reduces the size of the stomach and reroutes the digestive system. This results in both restriction of food intake and malabsorption, leading to significant weight loss. The surgery is considered highly effective for morbidly obese individuals and also helps improve obesity-related health issues like diabetes, hypertension, and sleep apnea. However, it requires lifelong dietary changes and nutritional supplements to avoid deficiencies.

Semaglutide is a weight-loss medication that mimics a hormone regulating appetite and food intake. In the UK, it is marketed under the brand names Ozempic (for diabetes) and Wegovy (for obesity). It is prescribed to individuals struggling with weight management, often in conjunction with diet and exercise.

The Roux-en-Y gastric bypass is a common bariatric surgery where the stomach is divided into a small upper pouch and a larger lower portion. The small intestine is then rearranged to connect with the new stomach pouch. This procedure reduces food intake and limits calorie absorption, making it highly effective for weight loss.

Wegovy (semaglutide) is a medication that helps with weight loss by mimicking a hormone that regulates appetite. It is prescribed to individuals with obesity or those with weight-related health problems. In the UK, Wegovy has been approved for NHS use for patients who meet certain criteria, providing a non-surgical option for those seeking medical weight-loss assistance.

After lap band surgery, patients must follow a specific diet to maximize the success of the procedure and avoid complications. Immediately post-surgery, a liquid diet is followed by a progression to soft foods and, eventually, solid foods. The diet must be high in protein and low in sugar, with small, frequent meals to avoid overfilling the stomach pouch created by the band.

RNY reversal is the process of undoing the Roux-en-Y gastric bypass. Although rare, reversals are sometimes necessary due to complications such as malnutrition, severe dumping syndrome, or other medical issues.

The lap band and sleeve gastrectomy are two different bariatric surgeries. The lap band is adjustable and reversible, involving the placement of a band around the upper stomach. The sleeve, on the other hand, is permanent and involves the removal of part of the stomach. Sleeve gastrectomy tends to offer more substantial long-term weight loss, but the lap band has fewer immediate risks.